Editas Medicine Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Good morning, everyone, for 40th Annual JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm the Senior Large-cap Biotech Analyst, and it's my pleasure to introduce Editas Medicine, and Chairman and CEO, Jim Mullen.
Please note that following the presentation, we will move right into a Q&A session, where you can send in your questions via the conference portal, and I'll do my best to work them into the conversation.
So with that, Jim, thanks, as always, for joining us today, and let me turn things over to you for an update on Editas.
Thank you, Cory, for the introduction. And to everyone, welcome to the Editas Medicine presentation. I was appointed as CEO 11 months ago, and at that time, I had a few objectives.
The first was to assess our science and the evolution of the science and gene editing, where is our technology differentiated and where should we
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |